Could your Sleep-Wake cycle be driving high blood pressure?

NCT ID NCT07770958

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study looks at whether a disrupted sleep-wake cycle is linked to higher blood pressure and poorer heart health in young adults aged 18 to 45 with high blood pressure. Participants wear a wrist monitor for 14 days, have their blood pressure tracked for 24 hours, and complete questionnaires about stress and sleep. Researchers will compare those with more disrupted circadian rhythms to those with fewer disruptions to see if there is a connection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Wrist actigraphy (MotionWatch 8) and 24-hour ambulatory blood pressure monitoring
What this could lead to
If a link is found, it could point toward sleep-focused strategies to help manage blood pressure in young adults with hypertension.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The circadian disruption index is research-only and not a clinical diagnosis, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adults aged 18 to 45 years with established essential arterial hypertension who meet all predefined eligibility criteria. Participants will be recruited from the clinical population of the participating study center. The study population will include both male and female participants. Individuals with shift work or night-duty work, secondary hypertension, previously diagnosed circadian rhythm sleep-wake disorders, clinically significant sleep-related breathing disorders, diabetes mellitus, significant cardiovascular disease other than uncomplicated essential hypertension, clinically significant renal or endocrine disease, or other conditions likely to substantially affect circadian rhythm or blood pressure measurements will be excluded.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 to 45 years. 2. Established diagnosis of essential arterial hypertension. 3. Stable antihypertensive treatment for at least 4 weeks before enrollment, when pharmacological treatment is prescribed. 4. Ability and willingness to undergo 14 consecutive days of wrist actigraphy using the CamNtech MotionWatch 8. 5. Ability and willingness to undergo 24-hour ambulatory blood pressure monitoring. 6. Ability to provide written informed consent. Exclusion Criteria: 1. Shift work or night-duty work. 2. Known secondary hypertension. 3. Previously diagnosed circadian rhythm sleep-wake disorder. 4. Known obstructive sleep apnea or other clinically significant sleep-related breathing disorder. 5. Known clinically significant cardiovascular disease other than uncomplicated essential arterial hypertension. 6. Diabetes mellitus. 7. Chronic kidney disease with clinically significant renal impairment. 8. Active thyroid disease or other clinically significant endocrine disorder that may affect blood pressure or circadian rhythm. 9. Current treatment with medications known to substantially alter sleep-wake rhythm or circadian timing. 10. Regular use of hypnotic or sedative medication that could substantially affect actigraphic sleep assessment. 11. Pregnancy. 12. Inability to comply with study procedures or insufficient actigraphy/ABPM recording quality. 13. Any acute illness or unstable medical condition that, in the investigator's opinion, could substantially influence the study outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circadian disruption are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UMHAT " Tcaritca Yanna - ISUL"

    Sofia, Sofia, 1000, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.